动物造模,透明细胞肾癌,裸鼠模型 z-bio 2022-01-14 391

　　Objective: To use patient-derived clear cell renal cell carcinoma (ccRCC) cells (patient-derived cells, PDC) to detect the sensitivity of ccRCCPDC to molecularly targeted drugs for clinical diagnosis and treatment and experimental evidence.

　　Methods ccRCCPDC was subcutaneously inoculated into nude mice, and the molecular target drugs sunitinib, sorafenib, lenvatinib, regorafenib, and apatinib were administered orally And Anlotinib. The inhibitory effect of drugs on subcutaneous tumor formation of ccRCCPDC in nude mice. Collect cell and tumor tissue samples, use quantitative PCR technology to detect molecular targeted drug targets (VEGFR and other receptor tyrosine protein kinases and other protein kinases belonging to the ERK, AKT and MAPK signaling pathways), and determine their genetic background ccRCCPDC in the experiment In the process. Is it stable?

　　Result: We successfully obtained 5 strains of ccRCCPDC, inoculated the above-mentioned ccRCCPDC into nude mice, and obtained a nude mouse subcutaneous tumor model of kidney cancer. In the process of culturing PDC cells in vitro, molecular targeted drug targets are reduced or lost. However, due to the proliferation of PDC cells due to tumorigenesis in nude mice, the expression of molecular targeted drug targets in tumor tissues is relatively stable. It has inhibitory effect on subcutaneous molecular targeted drugs. The tumor formation of ccRCCPDC in nude mice has obvious individual differences in the source of patients. Among the selected targeted drugs, lenvatinib has stronger anti-tumor activity than some other targeted drugs.

　　Conclusion: This study can use patient-derived renal clear cell carcinoma cell lines to establish a kidney cancer animal model, which provides theoretical and experimental basis for related clinical diagnosis and treatment.